Predicting Impulse Control Disorders in Parkinson Disease through Incentive Biomarkers

Objective: This study was undertaken to evaluate whether the feedback-related negativity (FRN)-a neurophysiological marker of incentive processing-can be used to predict the development of impulse control disorders (ICDs) in Parkinson disease (PD). Methods: The longitudinal cohort consisted of conse...

Descripción completa

Detalles Bibliográficos
Autores: Marin-Lahoz, J, Martinez-Horta, S, Pagonabarraga, J, Horta-Barba, A, Aracil-Bolanos, I, Bejr-kasem, H, Sampedro, F, Campolongo, A, Kulisevsky, J
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2022
País:España
Institución:Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)
Repositorio:r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
OAI Identifier:oai:iibsantpau.fundanetsuite.com:p13022
Acceso en línea:https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=13022
https://ddd.uab.cat/record/283209
Access Level:acceso abierto
Palabra clave:dopamine receptor stimulating agent
biological marker
age
aged
Article
cohort analysis
controlled study
feedback related negativity
female
follow up
gambling
human
impulse control disorder
longitudinal study
major clinical study
male
monetary reward
nervous system parameters
Parkinson disease
prediction
prospective study
receiver operating characteristic
reward
sex
substitution therapy
complication
motivation
Biomarkers
Disruptive, Impulse Control, and Conduct Disorders
Dopamine Agonists
Humans
Motivation
Parkinson Disease
Prospective Studies
Descripción
Sumario:Objective: This study was undertaken to evaluate whether the feedback-related negativity (FRN)-a neurophysiological marker of incentive processing-can be used to predict the development of impulse control disorders (ICDs) in Parkinson disease (PD). Methods: The longitudinal cohort consisted of consecutive nondemented PD patients with no ICD history. We recorded FRN signals while they performed a gambling task. We calculated the mean amplitude difference between losses and gains (FRNdiff) to be used as a predictor of future ICD development. We performed prospective biannual follow-up assessments for 30 months to detect incident ICDs. Finally, we evaluated how basal FRNdiff was associated with posterior development of ICDs using survival models. Results: Between October 7, 2015 and December 16, 2016, we screened 120 patients. Among them, 94 patients performed the gambling and 92 completed the follow-up. Eighteen patients developed ICDs during follow-up, whereas 74 remained free of ICDs. Baseline FRNdiff was greater in patients who developed ICDs than in those who did not (-2.33 mu V vs -0.84 mu V, p = 0.001). No other significant baseline differences were found. The FRNdiff was significantly associated with ICD development in the survival models both when not adjusted (hazard ratio [HR] = 0.73, 95% confidence interval [CI] = 0.58-0.91, p = 0.006) and when controlling for dopamine replacement therapy, sex, and age (HR = 0.74, 95% CI = 0.55-0.97, p = 0.035). None of the impulsivity measures evaluated was related to ICD development. Interpretation: Reward-processing differences measured by FRN signals precede ICD development in PD. This neurophysiological marker permits identification of patients with high risk of ICD development.